Case Reports in Oncology最新文献_第9页

Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report. 在局部晚期不可切除皮肤鳞状细胞癌中使用术前免疫疗法：病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-10-03 eCollection Date: 2024-01-01 DOI: 10.1159/000540842

Sara Cerqueira Cabral, Emanuel Gouveia, Hugo Nunes, Patricia M Pereira

{"title":"Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report.","authors":"Sara Cerqueira Cabral, Emanuel Gouveia, Hugo Nunes, Patricia M Pereira","doi":"10.1159/000540842","DOIUrl":"https://doi.org/10.1159/000540842","url":null,"abstract":"Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease; however, for large head and neck cSCCs, it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC. A pilot study demonstrated a high rate of pathologic complete response using cemiplimab in the neoadjuvant setting.Case presentation: Here, we report the case of an 84-year-old man with two locally advanced unresectable cSCCs (a nasolabial lesion and a retroauricular lesion) treated with cemiplimab, for whom closer follow-up revealed a complete response of the retroauricular lesion and a partial response of the nasolabial lesion after 4 cycles. Patient will be submitted to nasolabial lesion resection.Conclusion: This illustrates the efficacy of the use of cemiplimab as preoperative therapy in advanced unresectable cSCC, facilitating a definitive surgical treatment.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1109-1114"},"PeriodicalIF":0.7,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Patient with Acute Promyelocytic Leukemia Treated with Isotretinoin: A Case Report. 用异维甲酸治疗急性早幼粒细胞白血病患者：病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-10-01 eCollection Date: 2024-01-01 DOI: 10.1159/000541328

Ilja Goldin, Michael Medinger, Jakob Passweg, Delia Halbeisen

引用次数: 0

Erythema Nodosum Secondary to CD5-Positive Diffuse Large B-Cell Lymphoma as a Paraneoplastic Symptom: A Case Report. 继发于 CD5 阳性弥漫大 B 细胞淋巴瘤的结节性红斑是一种副肿瘤症状：病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.1159/000540913

Masaya Abe, Kyotaro Ohno, Yuki Nakagawa, Yasuharu Sato, Hiroyuki Sugiura

{"title":"Erythema Nodosum Secondary to CD5-Positive Diffuse Large B-Cell Lymphoma as a Paraneoplastic Symptom: A Case Report.","authors":"Masaya Abe, Kyotaro Ohno, Yuki Nakagawa, Yasuharu Sato, Hiroyuki Sugiura","doi":"10.1159/000540913","DOIUrl":"https://doi.org/10.1159/000540913","url":null,"abstract":"Introduction: Erythema nodosum (EN) is the most common form of panniculitis. EN can be idiopathic or secondary to an underlying systemic disease, infection, drug use, or tumor. CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is a relapsed and refractory lymphoma, and further understanding of its pathology is required. We report a case of newly diagnosed CD5+ DLBCL with concomitant EN. Within the scope of our search, there were no reports of CD5+ DLBCL complicated with EN.Case presentation: A 79-year-old woman experienced swelling, warmth, redness, and pain in both legs and a mass lesion on the right side of the back at almost the same time. The respective lesions were diagnosed as EN and CD5+ DLBCL by biopsy. With chemotherapy, the lymphoma and EN improved in parallel courses. The patient has completed scheduled chemotherapy, and there has been no recurrence of swelling in the legs or mass on the right side of the back.Discussion: The lymphoma and EN developed simultaneously and followed a parallel clinical course after chemotherapy, suggesting that EN was a paraneoplastic symptom of CD5+ DLBCL. Recognizing and treating underlying malignancies in patients presenting with EN is crucial.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1094-1102"},"PeriodicalIF":0.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 0.7

Case Reports in Oncology Pub Date : 2024-09-26 eCollection Date: 2024-01-01 DOI: 10.1159/000541256

François Volery, Yara Banz, Alexander Heini, Marie-Noelle Kronig, Daniel Siegrist, Michael Daskalakis, Ulrike Bacher, Thomas Pabst

引用次数: 0

Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer: A Case Report and Review of the Literature. 转移性胃癌患者继发于 Pembrolizumab 的 Vogt-Koyanagi-Harada 类葡萄膜炎：病例报告和文献综述。

IF 0.7

Case Reports in Oncology Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI: 10.1159/000541133

Ryan A Denu, John J McDermott, Shivani C Patel, Tejal Patel, Sami S Dahr

{"title":"Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer: A Case Report and Review of the Literature.","authors":"Ryan A Denu, John J McDermott, Shivani C Patel, Tejal Patel, Sami S Dahr","doi":"10.1159/000541133","DOIUrl":"https://doi.org/10.1159/000541133","url":null,"abstract":"Introduction: Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by uveitis and exudative retinal detachments in the absence of ocular trauma or surgery. Neurological and cutaneous manifestations can also occur. Prior case reports have associated immune checkpoint inhibitors with a VKH-like disease.Case presentation: A 64-year-old woman presented with 3 months of epigastric pain, and subsequent endoscopy showed a large mass in the gastroesophageal junction. Staging imaging showed an FDG-avid para-aortic node, making the disease stage IV, and she was treated with systemic therapy with FOLFOX. Molecular profiling showed HER2 amplification and PDL1 positivity, so trastuzumab and pembrolizumab were added. PET and esophagogastroduodenoscopy with biopsies showed a complete radiologic and pathologic response to treatment. Chemotherapy was stopped, and she continued on trastuzumab and pembrolizumab maintenance. After about 18 months of treatment with pembrolizumab, she presented with painful blurry vision in both eyes. Ophthalmologic evaluation showed panuveitis, serous retinal detachment, bilateral uveal edema, and secondary angle closure, consistent with VKH-like uveitis. She was treated with local and systemic corticosteroids. Pembrolizumab was assessed as the most likely causative agent and was discontinued. Her ophthalmologic exam improved, and her visual acuity returned to baseline. She continues on trastuzumab maintenance, and most recent imaging shows no evidence of disease.Conclusion: Oncologists should be aware of VKH-like disease as a possible immune-related adverse event and seek urgent ophthalmologic consultation when such symptoms arise.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1071-1086"},"PeriodicalIF":0.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum. 勘误。

IF 0.7

Case Reports in Oncology Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.1159/000541305

引用次数: 0

Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review. 特克司他单抗是治疗复发性多发性骨髓瘤心包积液的有效方法：病例报告和文献综述。

IF 0.7

Case Reports in Oncology Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.1159/000540979

Sai Samyuktha Bandaru, Naveen Singh Multani, William Thomas Nauam, Cibar Benitez-Farina

{"title":"Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review.","authors":"Sai Samyuktha Bandaru, Naveen Singh Multani, William Thomas Nauam, Cibar Benitez-Farina","doi":"10.1159/000540979","DOIUrl":"https://doi.org/10.1159/000540979","url":null,"abstract":"Introduction: Multiple myeloma represents a malignant disorder of plasma cells. Extramedullary relapse in multiple myeloma is a rare occurrence, and pericardial involvement stands as an exceedingly uncommon manifestation. Only a few documented cases of pericardial effusion as an extramedullary relapse presentation of myeloma exist. Bispecific antibodies are emerging as a novel class of immunotherapy drugs for the treatment of relapsed refractory multiple myeloma patients who have experienced failure with four prior lines of therapy. According to a literature review, none of the reported cases with pericardial effusion relapsed myeloma have been treated with bispecific antibodies, given that these drugs have only recently gained approval.Case presentation: We present a rare case of a patient with pericardial effusion resulting from myeloma relapse, treated with teclistamab, a bispecific antibody, and achieving an excellent response.Conclusion: Bispecific antibodies, such as teclistamab, show great effectiveness as a treatment for patients with relapsed refractory multiple myeloma, including those with extramedullary disease.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1063-1069"},"PeriodicalIF":0.7,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for the Treatment of Unresectable Progressive Glioblastoma. 肿瘤治疗场（TTFields）疗法和洛莫司汀化疗用于治疗无法切除的进展期胶质母细胞瘤。

IF 0.7

Case Reports in Oncology Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.1159/000540669

Ertan Mergen, Sonja Landrock, Barbara Chizzali

{"title":"Tumor Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for the Treatment of Unresectable Progressive Glioblastoma.","authors":"Ertan Mergen, Sonja Landrock, Barbara Chizzali","doi":"10.1159/000540669","DOIUrl":"https://doi.org/10.1159/000540669","url":null,"abstract":"Introduction: Tumor Treating Fields (TTFields) therapy used concomitantly with maintenance temozolomide through second progression after radio-chemotherapy is associated with improved survival outcomes compared to adjuvant temozolomide alone in individuals with newly diagnosed glioblastoma (GBM). Lomustine (CCNU) is frequently used as monotherapy or concomitant with other chemotherapy regimens as second-line treatment for recurrent GBM.Case presentation: We report a 59-year-old female patient diagnosed with MGMT-promoter methylated, isocitrate dehydrogenase-wildtype GBM (World Health Organization Grade 4) who received TTFields therapy concomitant with first- and second-line chemotherapy following partial resection. The patient experienced tumor pseudoprogression/progression after three cycles of maintenance temozolomide/TTFields therapy and again after a further two cycles of procarbazine/CCNU/TTFields therapy, and was then switched to CCNU/TTFields therapy. During 18 months of treatment with concomitant TTFields therapy and CCNU, the patient experienced regression/reduction of both tumor volume and perifocal edema with tolerable hematotoxicity and was able to maintain a high rate of TTFields therapy usage. The patient ultimately died after developing chemotherapy-related acute myeloid leukemia.Conclusion: This patient case is reflective of the EF-14 study outcome using TTFields therapy beyond first progression concomitantly with chemotherapy. The observations from this case suggest that TTFields therapy concomitant with CCNU is a valuable treatment modality in patients with GBM, in this context.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1056-1062"},"PeriodicalIF":0.7,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Treatment of Unresectable BRCA1 L63*-Mutated Basal Cell Carcinoma Invading the Parietal Bone with Cisplatin and Fluorouracil: A Case Report. 用顺铂和氟尿嘧啶成功治疗侵犯顶骨的无法切除的 BRCA1 L63* 突变基底细胞癌：病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-09-20 eCollection Date: 2024-01-01 DOI: 10.1159/000541160

Saaya Yoshida-Akai, Taku Fujimura, Ryo Amagai, Yumi Kambayashi, Akira Hashimoto, Hitoshi Terui, Kenta Oka, Manami Watanabe-Takahashi, Emi Yamazaki, Kota Ohuchi, Yoshihide Asano

{"title":"Successful Treatment of Unresectable BRCA1 L63*-Mutated Basal Cell Carcinoma Invading the Parietal Bone with Cisplatin and Fluorouracil: A Case Report.","authors":"Saaya Yoshida-Akai, Taku Fujimura, Ryo Amagai, Yumi Kambayashi, Akira Hashimoto, Hitoshi Terui, Kenta Oka, Manami Watanabe-Takahashi, Emi Yamazaki, Kota Ohuchi, Yoshihide Asano","doi":"10.1159/000541160","DOIUrl":"https://doi.org/10.1159/000541160","url":null,"abstract":"Introduction: Basal cell carcinoma (BCC) is a common skin cancer that rarely metastasizes but can deeply infiltrate local tissues. The small number of unresectable BCC cases makes it difficult to conduct clinical trials, resulting in delays in the development of effective drugs for BCC. Cancer gene panel testing has led to an increasing number of new treatment proposals for patients with solid tumors for whom no standard treatment is available.Case presentation: We described a case of unresectable BRCA1 L63*-mutated BCC invading the parietal bone, which was successfully treated with cisplatin and fluorouracil.Conclusion: Our present case suggests that comprehensive mutation analysis by gene panel testing is important in advanced BCC because genes other than those involved in the hedgehog signaling pathway can be driver genes.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1050-1054"},"PeriodicalIF":0.7,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum. 勘误。

IF 0.7

Case Reports in Oncology Pub Date : 2024-09-20 eCollection Date: 2024-01-01 DOI: 10.1159/000541284

引用次数: 0